Senhwa Biosciences, Inc.
TWO: 6492.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jason Huang
- Headquarters
- New Taipei City, Taiwan
- IPO year
- 2014
- Market cap
- NT$4.6B
- Website
- https://www.senhwabio.com
Loading 6492…
Loading profile data…Frequently asked questions about 6492
What does Senhwa Biosciences, Inc. (6492.TWO) do?
Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in...
Where does 6492.TWO trade?
Senhwa Biosciences, Inc. (6492.TWO) trades on the Taipei Exchange.
What sector is 6492.TWO in?
Senhwa Biosciences, Inc. (6492.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Senhwa Biosciences, Inc.?
Jason Huang is the chief executive officer of Senhwa Biosciences, Inc. (6492.TWO).
Where is Senhwa Biosciences, Inc. headquartered?
Senhwa Biosciences, Inc. is headquartered in Taiwan.
Does 6492.TWO pay a dividend?
Senhwa Biosciences, Inc. (6492.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6492.TWO go public?
Senhwa Biosciences, Inc. (6492.TWO) completed its initial public offering in 2014.